PDCD1LG2 and neoplasm: However, the specific role of PD-L2 in LGGs and their therapeutic sensitivity to immunotherapy and TMZ-based chemotherapy have not been reported, and few studies have been performed to explore the relationship between PD-L2 and TIICs in the LGGs tumor immune microenvironment (TIME).